Fulcrum Therapeutics, Inc. (FULC)
FULC Stock Price Chart
Explore Fulcrum Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze FULC price movements and trends.
FULC Company Profile
Discover essential business fundamentals and corporate details for Fulcrum Therapeutics, Inc. (FULC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jul 2019
Employees
45.00
Website
https://www.fulcrumtx.comCEO
Alexander C. Sapir
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FULC Financial Timeline
Browse a chronological timeline of Fulcrum Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.29.
Earnings released on 29 Jul 2025
EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.45%.
Earnings released on 1 May 2025
EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.45%.
Earnings released on 25 Feb 2025
EPS came in at -$0.31 falling short of the estimated -$0.28 by -10.71%.
Earnings released on 13 Nov 2024
EPS came in at -$0.35 surpassing the estimated -$0.40 by +12.50%.
Earnings released on 31 Jul 2024
EPS came in at $0.87 surpassing the estimated $0.01 by +7.06K%, while revenue for the quarter reached $80.00M , beating expectations by +439.93%.
Earnings released on 13 May 2024
EPS came in at -$0.43 surpassing the estimated -$0.44 by +2.27%.
Earnings released on 27 Feb 2024
EPS came in at -$0.40 surpassing the estimated -$0.44 by +9.09%, while revenue for the quarter reached $871.00K , beating expectations by +89.35%.
Earnings released on 7 Nov 2023
EPS came in at -$0.39 surpassing the estimated -$0.44 by +11.36%, while revenue for the quarter reached $759.00K , beating expectations by +65.00%.
Earnings released on 3 Aug 2023
EPS came in at -$0.38 surpassing the estimated -$0.44 by +13.64%, while revenue for the quarter reached $880.00K , missing expectations by -21.43%.
Earnings released on 15 May 2023
EPS came in at -$0.41 surpassing the estimated -$0.47 by +12.77%, while revenue for the quarter reached $295.00K , missing expectations by -73.89%.
Earnings released on 9 Mar 2023
EPS came in at -$0.50 falling short of the estimated -$0.49 by -2.04%, while revenue for the quarter reached $685.00K , missing expectations by -58.48%.
Earnings released on 8 Nov 2022
EPS came in at -$0.50 surpassing the estimated -$0.62 by +19.35%, while revenue for the quarter reached $1.18M , missing expectations by -53.48%.
Earnings released on 11 Aug 2022
EPS came in at -$0.83 falling short of the estimated -$0.66 by -25.76%, while revenue for the quarter reached $1.88M , missing expectations by -36.51%.
Earnings released on 9 May 2022
EPS came in at -$0.64 falling short of the estimated -$0.63 by -1.59%, while revenue for the quarter reached $2.59M , missing expectations by -34.28%.
Earnings released on 3 Mar 2022
EPS came in at -$0.58 surpassing the estimated -$0.65 by +10.77%, while revenue for the quarter reached $5.06M , beating expectations by +88.74%.
Earnings released on 4 Nov 2021
EPS came in at -$0.57 surpassing the estimated -$0.64 by +10.94%, while revenue for the quarter reached $4.94M , beating expectations by +119.33%.
Earnings released on 10 Aug 2021
EPS came in at -$0.60 surpassing the estimated -$0.65 by +7.69%, while revenue for the quarter reached $4.38M , beating expectations by +173.81%.
Earnings released on 6 May 2021
EPS came in at -$0.54 surpassing the estimated -$0.66 by +18.18%, while revenue for the quarter reached $4.79M , missing expectations by -15.38%.
Earnings released on 4 Mar 2021
EPS came in at -$0.64 surpassing the estimated -$0.73 by +12.33%, while revenue for the quarter reached $4.23M .
Earnings released on 10 Nov 2020
EPS came in at -$0.70 falling short of the estimated -$0.66 by -6.06%, while revenue for the quarter reached $1.85M , beating expectations by +8.33%.
FULC Stock Performance
Access detailed FULC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.